Intelligence

Analysis

Single-Tube Myeloma MRD: Inspect the Discordant Cases Behind the Kappa

A 39-patient paired comparison reports substantial agreement between single-tube and EuroFlow assays. Detection thresholds and discordant results remain essential to interpretation.

Technical Review of a peer-reviewed original study in Journal of Clinical Laboratory Analysis (2026-08-11). Historical or study-specific evidence; original CFCM educational appraisal.

Start with the measurement question

A summary agreement statistic can conceal the cases that matter most when a laboratory considers changing an MRD workflow. Read the threshold and the contingency table together.

What the primary paper contributes

Bae and colleagues compared a single-tube 10-color assay with EuroFlow next-generation flow in a final cohort of 39 myeloma patients. At the analytical threshold, the assays classified 19 and 15 samples as positive, respectively, with kappa 0.79. At the 0.001% clinical cutoff, the corresponding counts were 17 and 14, with kappa 0.84. The discussion notes the small, single-center cohort and that observer reproducibility was not evaluated. These findings support a focused method appraisal; they do not establish universal equivalence or a treatment rule. Read the primary article (DOI 10.1002/jcla.70332).

Original CFCM conceptual checklist: Threshold; Denominator; Discordance. No patient data or source figure reproduced.
Original CFCM conceptual diagram. Educational synthesis; not clinical validation.

A proposed local review

For a local verification plan, define the intended decision before selecting the comparison metric. Retain the event denominator and analytical limit for each sample; compare borderline and discordant calls rather than reporting only a correlation coefficient.

Keep the limits visible

Keep operational convenience, quantitative agreement and prognostic performance as separate claims. The paper’s survival comparisons do not remove its cohort limitations. No new patient data were analyzed here, and the original CFCM diagram contains no reconstructed patient plots.

Daily Learning Pill

A strong kappa does not explain every discordant result. Keep the threshold visible.

Explore CFCM Resources and Troubleshooting. Review by ChatGPT/Codex, not independent scientific review or clinical validation.